Efficacy of cisplatin-based neoadjuvant chemotherapy and risk factors for residual extravesical disease in muscle-invasive bladder cancer: insights from a nationwide cohort
Ryoichi Saito(University of Miyazaki), Taketo Kawai(National Center for Global Health and Medicine), Sho Sekito(Aichi Cancer Center), Tomokazu Sazuka(Chiba University), Fumihiko Urabe(Jikei University School of Medicine), Keiji Yasue(Higashi Nagoya National Hospital), Wataru Fukuokaya(Jikei University School of Medicine), Yoshiyuki Matsui(Tokyo National Hospital), Shuichi Tatarano(Kagoshima University), Katsuyoshi Hashine(Shikoku Cancer Center), Takeshi Sano(Tokushima University), Kenichiro Shiga(Harasanshin Hospital), Yusuke Sugino(Mie University), Takuji Hayashi(Osaka International Cancer Institute), Koichiro Wada(Shimane University), Junichi Inokuchi(Kyushu University), Hiroaki Matsumoto(Yamaguchi University), Rikiya Taoka(Kagawa University), Soki Kashima(Akita University), Makito Miyake(Nara Medical University), Kiyoaki Nishihara(Kurume University), Yuto Matsushita(Hamamatsu University School of Medicine), Yoji Murakami(Kumamoto University), Hirohito Naito(Kagawa University), Noriya Yamaguchi(Tottori University), Hiroyuki Nishiyama(University of Tsukuba), Shotaro Nakanishi(University of the Ryukyus), Kei Daizumoto(Tokushima University), Jun Miki(Jikei University School of Medicine), Takashige Abe(Hokkaido University), Hidefumi Kinoshita(Kansai Medical University), Ayumu Matsuda(Tokyo National Hospital), Shingo Yamamoto(Hyogo University), Minoru Katō(Osaka Metropolitan University), Takashi Kawahara(University of Tsukuba), Hiroshi Kitamura(University of Toyama), Shingo Hatakeyama(Hirosaki University), Masato Fujii(Niigata University), Naotaka Nishiyama(University of Toyama), Ryo Maruyama(Niigata University)
Cited by 5
Related Papers
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Extracellular vesicles as biomarkers and therapeutic targets for cancer
|American Journal of Physiology-Cell Physiology|2019|412
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411
A Glycine-rich RNA-binding Protein Mediating Cold-inducible Suppression of Mammalian Cell Growth
|The Journal of Cell Biology|1997|388